Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJID (3) Autor Curcio,Daniel (3) Barcelona,Laura (1) Cané,Alejandro (1) Dowzicky,Michael J (1) Fernández,Francisco (1) García,Patricia (1) Ronzon,Bernardo (1) Rossi,Flávia (1) Stamboulian,Daniel (1) Mais... Palavra-chave Tigecycline (2) Antibacterial resistance (1) Latin America (1) Off-label (1) Surveillance (1) Ventilator-associated pneumonia (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Info:eu-repo/semantics/other (1) Ano 2013 (1) 2008 (2) País Brazil (3) Idioma Inglês (3)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 3 Primeira ... 1 ... Última A comparative analysis between survivors and nonsurvivors patients treated with tigecycline BJID Curcio,Daniel. Tipo: Info:eu-repo/semantics/other Ano: 2013 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000200030 Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry BJID Curcio,Daniel; Fernández,Francisco; Cané,Alejandro; Barcelona,Laura; Stamboulian,Daniel. Tigecycline is the first of a new class of antibiotics named glycylcyclines and it was approved for the treatment of complicated intra-abdominal infections and complicated skin and skin structure infections. Notwithstanding this, tigecycline's pharmacological and microbiological profile which includes multidrug-resistant pathogens encourages physicians' use of the drug in other infections. We analyzed, during the first months after its launch, the tigecycline prescriptions for 113 patients in 12 institutions. Twenty-five patients (22%) received tigecycline for approved indications, and 88 (78%) for "off label" indications (56% with scientific support and 22% with limited or without any scientific support). The most frequent "off label" use was ventilator... Tipo: Info:eu-repo/semantics/article Palavras-chave: Tigecycline; Off-label; Ventilator-associated pneumonia. Ano: 2008 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702008000300007 Rates of antimicrobial resistance in latin america (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics BJID Rossi,Flávia; García,Patricia; Ronzon,Bernardo; Curcio,Daniel; Dowzicky,Michael J. As a part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), Gram-positive and Gram-negative bacterial isolates were collected from 33 centers in Latin America (centers in Argentina, Brazil, Chile, Colombia, Guatemala, Honduras, Jamaica, Mexico, Panama, Puerto Rico, and Venezuela) from January 2004 to September 2007. Argentina and Mexico were the greatest contributors of isolates to this study. Susceptibilities were determined according to Clinical Laboratory Standards Institute guidelines. Resistance levels were high for most key organisms across Latin America: 48.3% of Staphylococcus aureus isolates were methicillin-resistant while 21.4% of Acinetobacter spp. isolates were imipenem-resistant. Extended-spectrum β-lactamase were reported in... Tipo: Info:eu-repo/semantics/article Palavras-chave: Antibacterial resistance; Latin America; Tigecycline; Surveillance. Ano: 2008 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702008000500012 Registros recuperados: 3 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco